Chemicals and Drugs [D] » Amino Acids, Peptides, and Proteins [D12] » Proteins » Blood Proteins » Serum Globulins » Immunoglobulins » Antibodies » Antibodies, Monoclonal » Antibodies, Monoclonal, Humanized » Nivolumab
Chemicals and Drugs [D] » Amino Acids, Peptides, and Proteins [D12] » Proteins » Globulins » Serum Globulins » Immunoglobulins » Antibodies » Antibodies, Monoclonal » Antibodies, Monoclonal, Humanized » Nivolumab
Chemicals and Drugs [D] » Amino Acids, Peptides, and Proteins [D12] » Proteins » Blood Proteins » Immunoproteins » Immunoglobulins » Antibodies » Antibodies, Monoclonal » Antibodies, Monoclonal, Humanized » Nivolumab
Description
A genetically engineered, fully humanized immunoglobulin G4 monoclonal antibody that binds to the PD-1 RECEPTOR, activating an immune response to tumor cells. It is used as monotherapy or in combination with IPILIMUMAB for the treatment of advanced malignant MELANOMA. It is also used in the treatment of advanced or recurring NON-SMALL CELL LUNG CANCER; RENAL CELL CARCINOMA; and HODGKIN'S LYMPHOMA. MeSH
Hierarchy View
Phase 2 Indicated Drugs (1)
Hierarchy Tree View
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
